No label defined (Q31792)
Jump to navigation
Jump to search
No description defined
- The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
There is evidence that gender-affirming hormone treatment (GAHT) for transgender individuals modulates their risk for specific malignancies including breast and prostate cancer, and meningiomas. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
However, there is insufficient data to make precise risk estimates accounting for age and inherited cancer risk. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
As such, screening recommendations remain broad. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Even less evidence exists for best practice in the management of active or historical cancers in the transgender population. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Guidance is therefore mainly extrapolated from cisgender populations but with considerations of the significant benefits of GAHT in the face of any hormonal risk. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Clinical experience, the multidisciplinary team and shared decision making with the patient are vital in providing person-centred care, while further research is acquired. (English)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. (English)
2024
Alison May (English)
Berner (English)
AM
Sarah Elizabeth (English)
Atkinson (English)
SE
13 September 2024
13 September 2024
Declaration of Competing Interest AMB has received honoraria for non-promotional education on cancer care in transgender patients from Pfizer, Lilly and Astellas, and a fellowship grant to employ staff for the UK Cancer and Transition Service from Gilead. (English)